Variation in almotriptan effectiveness according to different prophylactic treatments.
OBJECTIVE
To evaluate the effect of different migraine prophylaxis medications on subject responsiveness to almotriptan.


BACKGROUND
There is evidence supporting an increase of responsiveness of symptomatic medications for migraine attacks by some prophylactic treatments although this has not been probed.


METHODS
A total of 345 patients (230 women, mean age 37.3) with episodic or chronic migraine were classified according to the prophylaxis they were taking in the following groups: (1) no prophylactic medication; (2) propranolol; (3) topiramate; (4) flunarizine. Decrease in Analogical Visual Scale and pain-free at 2 hours after almotriptan intake was assessed at 2 months. Side effects and discontinuation or treatment were also assessed.


RESULTS
Headache severity was reduced 4.2 in control group, 5.3 in propranolol group, 4.1 in topiramate group, and 4.0 in flunarizine group, whereas pain-free status was achieved in 37.3%, 48.7%, 36.1%, and 38.1% respectively. These two parameters were statistically significative between propranolol and control groups. Side effects were similar in all groups.


CONCLUSIONS
Our results displayed a higher efficacy of almotriptan in propranolol group and we hypothesized it may be due to a common mechanism of action at serotoninergic receptors.
Puerta de Hierro University Hospital - Neurology, Madrid, Spain.
Pedro Emilio
PE
Bermejo
Rodolfo
R
Dorado
Jose Maria
JM
Gomez-Arguelles
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004347:Drug Interactions / Q000502:physiology; D004359:Drug Therapy, Combination; D005260:Female; D005444:Flunarizine / Q000494:pharmacology*; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D010147:Pain Measurement; D011433:Propranolol / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D000077236:Topiramate; D016896:Treatment Outcome; D014363:Tryptamines / Q000494:pharmacology*; D055815:Young Adult
D000319:Adrenergic beta-Antagonists; D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D000077236:Topiramate; C409045:almotriptan; D005632:Fructose; D011433:Propranolol; D005444:Flunarizine